RTACC

1. RTACC predicts multi-domain intervention response in humans (combined with clinical information in participants with mild cognitive impairment) (AUC 0.73, 95% CI: 0.62-0.84).

   “Logistic regression analysis demonstrated that RTACC combined with clinical information identified good responders with an area under the receiver operating characteristic curve of 0.73 (95% CI: 0.62-0.84).”

   Human trialcombined with clinical information in participants with mild cognitive impairment24 weeksn = 130

   Developing digital biomarker for predicting cognitive response to multi-domain intervention

   Scientific reports·Jan 30, 2026

1. RTACC predicts brain-derived neurotrophic factor in humans (beta coefficient = - 3.13 ± 1.64, P = 0.057).

   “RTACC also showed a marginal effect on changes in brain-derived neurotrophic factor levels (beta coefficient = - 3.13 ± 1.64, P = 0.057).”

   Human trialin participants with mild cognitive impairment enrolled in the intervention arm of the SUPERBRAIN-MEET trial24 weeksn = 130

   Developing digital biomarker for predicting cognitive response to multi-domain intervention

   Scientific reports·Jan 30, 2026

More on Brain-derived neurotrophic factor

1. RTACC predicts cognitive function in humans (beta coefficient = -11.90 ± 3.78, T = - 3.14, P = 0.002).

   “Linear regression analysis revealed a significant association between RTACC and changes in Repeatable Battery for the Assessment of Neuropsychological Status scores from baseline to 24 weeks”

   Human trialin participants with mild cognitive impairment enrolled in the intervention arm of the SUPERBRAIN-MEET trial24 weeksn = 130

   Developing digital biomarker for predicting cognitive response to multi-domain intervention

   Scientific reports·Jan 30, 2026